M. Kachura

Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection

Annie Shen, K. Jooss, C. Scallan, 2022, Nature Communications.

A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2

Annie Shen, K. Jooss, C. Scallan, 2021 .

Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non‐human primates, and human primary cells

S. A. Kell, R. Coffman, P. Traquina, 2019, International immunopharmacology.

Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen

R. Coffman, R. Kiwan, G. Ott, 2016, Bioconjugate chemistry.

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys

S. A. Kell, R. Coffman, R. Kiwan, 2016, The Journal of Immunology.

Isolation and Culture of Adult Mouse Cardiac Myocytes for Signaling Studies

Meghdad Rahdar, Luyi Li, Julie N. R. Collins, 2003 .

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults

Kyounghwa Bae, K. Jooss, C. Scallan, 2023, Nature communications.

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.

R. Coffman, M. Foster, E. Hessel, 2009, The Journal of clinical investigation.